Thrilled that one of my minions is following in my footsteps and has the honor to learn from the best @CancerBioEmory and @WinshipAtEmory this fall! Excited to hear great things from Anna along her journey!.

Excited to have worked with @sarajwong and COMPASS all year to produce this programming for @ASCBiology! If you're attending #cellbio2023, be sure to swing by and catch this awesome, trainee-organized, professional development programming!.

It's been a blast working with @sarajwong to lead COMPASS in @ASCBiology over the past year. If you're an ASCB trainee and interested in advocating for our constituents and ensuring our voice is heard, please feel free to apply to COMPASS!.

So grateful to @mary_munson4 for her leadership and mentorship over the years. Could not be prouder to have a wonderful leader for @ASCBiology into the future. Congrats to Mary and to ASCB!.

So grateful to this wonderful crew for helping make this project such a success! Congrats @BajAnna451 @isaiahking03 and Daniel who still doesn’t have Twitter yet! Thanks for all your work and dedication to our project!.

RT @sowalsky: Standing with his dream team (@BajAnna451 @isaiahking03 and Daniel Low), @s_wilkinson88 regales us about cross-talk between p….

RT @ASCBiology: Join COMPASS! They create programming, science advocacy, and outreach opportunities and foster community and connection bet….

RT @ThePhDPlace: Before the deadline vs after the deadline

Couldn't be prouder of my 2017 summer student who had the courage to come back 2 years later for another round. Watch out, Greensboro, Dr Atway is on her way!.

RT @UGAAthletics: The 40 year curse is no more. Take it in Dawg Fans. We did it. #GoDawgs.

RT @yungjoc650: DAWGSSSS might just be those MFers!!!!!.

RT @Braves: THE ATLANTA BRAVES ARE WORLD SERIES CHAMPIONS!. #BattleATL | #ForTheA

Working with COMPASS for the past several years has been one of the greatest highlights of my career. Incredible opportunity to contribute to the direction of the Society, and IMMENSE networking opportunities. As the current COMPASS chair, I strongly encourage everyone to apply!.

RT @AdrianaBankston: As a trainee, COMPASS was my first leadership experience advocating for #ECRs, provided a great network of folks whom….

A tremendous volume of data accompanies this paper, both in the Supplementary data, as well as raw data deposited in dbGaP and TCGA. #openaccess #datasharing. We look forward to seeing similar datasets deposited so we can validate our findings, and others can validate theirs.

All of this work over the past 5 years would be impossible without the help of so many. Thank you to all the patients who participate in these studies. Thanks to @sowalsky for his mentoring. And of course, our funding sources @PCF_Science @cdmrp @IRPatNIH.

By combining pre-tx imaging with our model, the prediction model improved to AUC=0.98. This simple model of only 5 features may show great promise in selecting pts most likely to benefit. If a tumor is determined to be INR, pts could be treated differently, saving valuable time.

We know from previous studies that patients with very good responses to intense neoadjuvant ADT are at far less risk of recurrence. However, TCGA cases predicted to respond to therapy still recurred at the same rate, meaning there is a subset of patients who may benefit.

This prediction model correlated well with genomic heterogeneity. When we computed both genomic heterogeneity and a prediction of poor response using these factors from high-risk prostate TCGA cases, genomic diversity again correlated with INR probability.

We next took the top genomic and histologic features that were enriched in INRs (IDC, chr10q loss, ERG, and TP53) and used them to build a prediction model for response to intense neoadjuvant ADT. On their own, a probability cutoff of 60% predicts poor response with AUC=0.89.